BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix Acquisition Corp. II worth $450 million in proceeds.